Mohamed Hassan Ismail
Urology Department, Al Azhar University, Bab El-Shaa'rya Hospital, Cairo, Egypt.
Arab J Urol. 2013 Dec;11(4):398-404. doi: 10.1016/j.aju.2013.08.013. Epub 2013 Sep 29.
To evaluate whether tamsulosin hydrochloride is effective as an adjunctive medical therapy to increase the effectiveness of extracorporeal shock-wave lithotripsy (ESWL) for treating ureteric stones, and minimises the use of analgesic drugs after the procedure.
To treat single ureteric stones of 5-15 mm in diameter, 130 patients were treated with ESWL. After treatment, equal numbers of patients were randomly assigned to receive either the standard medical therapy alone (controls) or combined with 0.4 mg tamsulosin daily for ⩽12 weeks. All patients were followed up for 3 months or until an alternative treatment was offered.
At 3 months the treatment was considered to be clinically successful in 55/65 (85%) of those receiving tamsulosin and in 58/65 (89%) of the controls (P = 0.34). When patients were classified according to stone size the success rate was similar in both groups (P = 0.22) for those with a stone of >10 mm. However, ureteric colic was reported in 12% of patients treated with standard therapy but in only 5% of those treated with tamsulosin (P = 0.006). The mean cumulative diclofenac dose was 380 mg/patient in the tamsulosin group and 750 mg/patient in the control group (P = 0.004).
This study showed the effectiveness of tamsulosin as an adjunctive medical therapy after ESWL for ureteric stones, but it did not improve stone clearance when treating ureteric stones. However, it decreased the use of analgesics and reduced the complication rate, especially for steinstrasse.
评估盐酸坦索罗辛作为辅助药物治疗,能否提高体外冲击波碎石术(ESWL)治疗输尿管结石的疗效,并减少术后镇痛药的使用。
为治疗直径5 - 15毫米的单一输尿管结石,130例患者接受了ESWL治疗。治疗后,将等量患者随机分为两组,一组仅接受标准药物治疗(对照组),另一组联合每日服用0.4毫克坦索罗辛,疗程≤12周。所有患者随访3个月或直至接受其他治疗。
3个月时,接受坦索罗辛治疗的患者中55/65(85%)临床治疗成功,对照组为58/65(89%)(P = 0.34)。按结石大小分类时,两组中结石>10毫米的患者成功率相似(P = 0.22)。然而,标准治疗组12%的患者报告有输尿管绞痛,而坦索罗辛治疗组仅5%(P = 0.006)。坦索罗辛组双氯芬酸的平均累积剂量为380毫克/患者,对照组为750毫克/患者(P = 0.004)。
本研究表明,坦索罗辛作为ESWL治疗输尿管结石后的辅助药物治疗有效,但在治疗输尿管结石时并未提高结石清除率。然而,它减少了镇痛药的使用并降低了并发症发生率,尤其是对石街的发生率。